Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:01:39 EDT Thu 14 May 2026
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q3.6132.20·134.710.1132.06-0.99-0.74,326.3570,15344,599133.77  134.65  131.81157.27  97.8616:35:49May 1315 min RT 2¢

Recent Trades - Last 10 of 44599
Time ETExPriceChangeVolume
16:35:49Q133.480.435
16:33:22Q132.63-0.4210
16:28:48Q131.50-1.555
16:27:44Q132.6223-0.42771
16:20:00Q132.06-0.991,084
16:15:49Q132.05-1.001
16:15:49Q132.05-1.002
16:15:49Q132.05-1.0013
16:15:49Q132.05-1.0016
16:15:01Q132.06-0.991

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-13 08:30U:GILDNews ReleaseGilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
2026-05-07 16:01U:GILDNews ReleaseGilead Sciences Announces First Quarter Financial Results
2026-05-01 06:00U:GILDNews ReleaseGilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
2026-04-29 08:30U:GILDNews ReleaseU.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
2026-04-28 08:45U:GILDNews ReleaseGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
2026-04-22 16:05U:GILDNews ReleaseGilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
2026-04-17 08:30U:GILDNews ReleaseGilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
2026-04-14 12:00U:GILDNews ReleasePEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
2026-04-07 08:30U:GILDNews ReleaseGilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
2026-04-01 16:13U:GILDNews ReleaseGilead Extends Tender Offer to Acquire Arcellx
2026-03-23 18:15U:GILDNews ReleaseGilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
2026-03-02 08:30U:GILDNews ReleaseGilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
2026-02-25 13:44U:GILDNews ReleaseGilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
2026-02-23 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2026-02-23 06:01U:GILDNews ReleaseGilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
2026-02-17 08:30U:GILDNews ReleaseGilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
2026-02-10 16:02U:GILDNews ReleaseGilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
2026-02-10 16:01U:GILDNews ReleaseGilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-06 08:30U:GILDNews ReleaseFDA Approves Label Update for Kite's Yescarta(TM) for Relapsed/Refractory Primary Central Nervous System Lymphoma